GSK's RSV Vaccine, Arexvy, Approved in US for Expanded Age Indication in Adults Aged 18-49 Years at Increased Risk
March 14, 2026
March 14, 2026
LONDON, England, March 14 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on March 13, 2026:
* * *
GSK's RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18-49 years at increased risk
- In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection/1*
*
GSK plc (LSE/NYSE: GSK) today announced that the US . . .
* * *
GSK's RSV vaccine, Arexvy, approved in US for expanded age indication in adults aged 18-49 years at increased risk
- In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection/1*
*
GSK plc (LSE/NYSE: GSK) today announced that the US . . .